Tango Therapeutics, Inc. (TNGX) /
The cash flow of Tango Therapeutics, Inc. over the past 6 years
Chart Tango Therapeutics, Inc.: operating cash flow, capital expenditures, free cash flow, fiscal 2020–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, Tango Therapeutics, Inc.'s operating cash flow was -$138.89M and its capital expenditures $1.05M, leaving free cash flow of -$139.93M. Free cash flow was above zero in 1 of the 6 years shown. It ranged from -$139.93M in fiscal 2025 to $68.97M in fiscal 2020. Capital expenditures were highest in fiscal 2022, at $7.69M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | -$138.89M | $1.05M | -$139.93M |
| 2024ended Dec 31, 2024 | -$131.5M | $754K | -$132.25M |
| 2023ended Dec 31, 2023 | -$117.98M | $1.53M | -$119.51M |
| 2022ended Dec 31, 2022 | -$109.08M | $7.69M | -$116.77M |
| 2021ended Dec 31, 2021 | -$59.53M | $1.84M | -$61.36M |
| 2020ended Dec 31, 2020 | $70.07M | $1.11M | $68.97M |
Fiscal years as Tango Therapeutics, Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Tango Therapeutics, Inc.
- The revenue of Tango Therapeutics, Inc.
- The profitability of Tango Therapeutics, Inc.
- The debt of Tango Therapeutics, Inc.
- All of Tango Therapeutics, Inc.'s financials, charted
Companies of a similar size
- MWAMueller Water Products, Inc.
- TNETTRINET GROUP, INC.
- PRIMPrimoris Services Corporation
- BNLBroadstone Net Lease, Inc.
- SMGScotts Miracle-Gro Co
Not investment advice. This page shows what Tango Therapeutics, Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.